Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
| Revenue (TTM) | $18.46M |
| Gross Profit (TTM) | $1.72M |
| EBITDA | $-2.30M |
| Operating Margin | -3569.00% |
| Return on Equity | -2.92% |
| Return on Assets | -3.47% |
| Revenue/Share (TTM) | $6.60 |
| Book Value | $15.72 |
| Price-to-Book | 4.74 |
| Price-to-Sales (TTM) | 13.12 |
| EV/Revenue | 10.38 |
| EV/EBITDA | 0.23 |
| Quarterly Earnings Growth (YoY) | 487.60% |
| Quarterly Revenue Growth (YoY) | -89.50% |
| Shares Outstanding | $3.27M |
| Float | 533,990 |
| % Insiders | 59.70% |
| % Institutions | 37.27% |
Volatility is currently contracting
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.84.
Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026 Sol-Gel signed an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in India NESS ZIONA, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.
